London, Feb 15, 2026, 13:20 GMT — Market closed
- Haleon shares closed at 409.2 pence on Friday, up 0.64%. (Investing)
- The company is scheduled to report full-year 2025 earnings on Feb. 25. (MarketWatch)
Haleon shares ended Friday slightly higher, closing at 409.2 pence in London trade. With markets shut over the weekend, the stock goes into Monday’s session with attention turning to the next company catalyst. (Hargreaves Lansdown)
Haleon has flagged Feb. 25 for its full-year 2025 results, a date investors have marked as the next real test of its growth and margin story. The company’s calendar also shows the event on its investor site. (Haleon Corporate)
That matters because the consumer-health group heads into results with questions hanging over North America demand, pricing, and how fast its cost programme can show up in profit. Traders will be looking for clean numbers, but the tone of the outlook tends to do the work in this name.
On Friday, the shares traded between 403.9 pence and 410.7 pence, after opening at 405.5 pence. Volume was about 24.4 million shares, well above the prior day’s roughly 11.0 million. (Yahoo Finance)
In January, Haleon told investors it was reshaping its operating model, including creating a Chief Growth Officer role and splitting its structure into six operating units, with changes expected by mid-2026. Chief executive Brian McNamara said the overhaul “will result in a simpler and more agile and efficient organisation.” (Haleon Corporate)
The rework sits alongside a longer-running push on productivity. Haleon has previously pointed to 800 million pounds of gross productivity savings over five years and tied that effort to its medium-term profit ambitions, according to a Reuters report. (Reuters)
But the downside case has not gone away. Haleon cut its 2025 revenue growth forecast in July after a U.S.-led slowdown in North America, its biggest market, with the company pointing to weaker consumer confidence and stiffer competition. Organic revenue growth strips out currency moves and recent deals; at the time Haleon guided to about 3.5% for the year, down from a prior 4%-6% range, and Jefferies analysts warned: “The organic sales growth guide cut is more extreme than feared.” (Reuters)
A later Reuters report in October showed signs of stabilisation, with Haleon citing strong Sensodyne demand and market-share gains in the U.S. and India, even as the broader consumer backdrop stayed tricky. JPMorgan analysts cautioned that “the weak U.S. market consumption remains a concern” heading into 2026. (Reuters)
For the week ahead, investors will focus on whether Feb. 25 brings firmer guidance on sales growth and profit, and how quickly the company expects its organisational changes to feed through. Haleon’s results page lists the Feb. 25 event and a Q&A webcast. (Haleon Corporate)
